Skip to main content

Bristol-Myers Squibb Company (BMY-N) Quote

Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 66.70
Day High 67.21
Open:66.75
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

New Study Indicates 'Helper' Cells May Kill Cancerous Tumors
- PR Newswire - Thu Jan 16, 8:00AM CST
PR Newswire - CMTX
Thu Jan 16, 8:00AM CST
USA News Group - A new study out suggests that T cells are a subset of lymphocytes (white blood cells), which play a key role in the body's immune response. This new information could prove to be a key in unlocking "helper" cells that could aid in cancer therapy.
Just - Evotec Biologics Announces Product Development And Manufacturing Agreement With Oncoresponse
- ACCESSWIRE - Thu Jan 16, 12:41AM CST
ACCESSWIRE - CMTX
Thu Jan 16, 12:41AM CST
JUST - EVOTEC BIOLOGICS WILL APPLY ITS FULLY INTEGRATED TECHNOLOGY PLATFORM IN ORDER TO ACCELERATE ONCORESPONSE'S LEAD PRODUCT CANDIDATE THROUGH DEVELOPMENT AND INTO THE CLINIC
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer
- BusinessWire - Wed Jan 15, 5:59AM CST
BusinessWire - CMTX
Wed Jan 15, 5:59AM CST
Bristol-Myers Squibb Company (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. The FDA has granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of May 15, 2020.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 62.55 +6.67% increase
on 01/03/20
Period Open:64.11
Price movement based on the high, low and last over the given period.
67.21 -0.73% decrease
on 01/17/20
+2.61 (+4.07%) increase
since 12/17/19
3-Month 52.38 +27.38% increase
on 10/18/19
Period Open:52.42
Price movement based on the high, low and last over the given period.
67.21 -0.73% decrease
on 01/17/20
+14.30 (+27.28%) increase
since 10/17/19
52-Week 42.48 +57.06% increase
on 07/23/19
Period Open:49.60
Price movement based on the high, low and last over the given period.
67.21 -0.73% decrease
on 01/17/20
+17.12 (+34.52%) increase
since 01/17/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies